Journal
JOURNAL OF CLINICAL MEDICINE
Volume 10, Issue 19, Pages -Publisher
MDPI
DOI: 10.3390/jcm10194586
Keywords
resistant migraine; CGRP; oxidative stress; biomarkers; medication-overuse headache
Categories
Ask authors/readers for more resources
The study demonstrates that targeted antibodies against CGRP and its receptor are effective tools for treating high-frequency resistant migraine and medication-overuse headache. The treatment shows precocious effects with high individual responder rates, significantly improving biological and clinical features.
Patients with high-frequency resistant migraine and medication-overuse headache are still the main clinical challenge in tertiary headache centers. The approval of targeted antibodies against the calcitonin gene-related peptide (CGRP) and its receptor represents a powerful instrument. In this study, we observed how biological and clinical features of resistant migraineurs responded to erenumab, fremanezumab, or galcanezumab. We found a reduction in advanced oxidation protein products (AOPP) as a biomarker of improved redox state after six months of treatment. We also found that treatment efficacy was precocious and maintained with high individual responder rates. In particular, seven out of ten patients achieved a reduction of 50% from the baseline at three months, which was maintained at six months, while about one out of our patients experienced a 75% reduction in headache frequency from the first month of treatment. The migraine disability assessment (MIDAS) and the associated fatigue, anxiety, and sleep quality also significantly improved. The allodynia symptom dropped from moderate/severe to mild/absent as a sign of central sensitization reduction. Our study confirmed the safety and efficacy of CGRP inhibition in real-life, high-challenging patients. Additional evidence is needed to understand the role of oxidative stress as a migraine biomarker.
Authors
I am an author on this paper
Click your name to claim this paper and add it to your profile.
Reviews
Recommended
No Data Available